Dr. Westin on Subgroup Analysis of ZUMA-7 of Elderly Patients With R/R DLBCL

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial (NCT03391466).

Investigators stratified efficacy outcomes for those treated with axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed CAR T-cell therapy, by age among adult patients in the population.

Patients aged 65 years or older are an important subset of patients, as they may not tolerate high-dose chemotherapy, and may not be eligible for curative intent approaches, Westin says. However, patients in this age group did better with CAR T-cell therapy than with chemotherapy in terms of their response rates, progression-free survival, and had early trends toward improved overall survival, Westin explains.

Moreover, quality of life was better for patients who received CAR T-cells, Westin adds. Standard-of-care, high-dose chemotherapy had a rapid and a persistent drop in patient quality of life, Westin explains. Older patients in ZUMA-7 had an initial drop in their quality of life following treatment with axi-cel, but quickly rebounded to baseline or better, Westin continues. Overall, axi-cel should be considered a viable option for patients who are age 65 years or older in the second line, Westin concludes.

Related Videos
Eugenia Girda, MD, FACOG
Scott Tagawa, MD, MS, FACP
Coral O. Omene, MD, PhD
Colin E. Champ, MD
Eunice Wang, MD
Henry S. Park, MD, MPH
Dana B Cardin, MD, MSCI
Jeffery Zonder, MD
Susan Bal, MD
Anne Chiang, MD, PhD
Related Content